Ensitrelvir

126 interactions 10 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Cabozantinib (Thyroid Cancer) Brexpiprazole Ifosfamide Injection Olaparib Docetaxel Erdafitinib
113 Contraindicated 13 Major
All (126) Contraindicated (113) Major (13)

Contraindicated

Ensitrelvir Omeprazole Gastrobim Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Sertraline Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Buprenorphine Belbuca Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of renal and/or hepatic impairment Details Ensitrelvir Simvastatin Flolipid Explained Increased simvastatin exposure and an increased risk of simvastatin-related adverse events Details Ensitrelvir Abemaciclib Verzenio Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Acalabrutinib Calquence Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Alpelisib Piqray Increased CYP3A/BCRP substrate exposure and an increased risk of adverse reactions Details Ensitrelvir Apixaban Eliquis Explained Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details Ensitrelvir Apremilast Otezla Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Aripiprazole Injection Abilify Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Asciminib Scemblix Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Atogepant Qulipta Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Avapritinib Ayvakit Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Avatrombopag Doptelet Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Belumosudil Rezurock Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Atorvastatin Atorvaliq Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Cariprazine Vraylar Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Abiraterone Abirtega Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Aficamten Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Alfuzosin UroXatral Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Amlodipine Amvaz® Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Avanafil Stendra Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Axitinib Inlyta Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Bedaquiline Sirturo Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Bosutinib Bosulif Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Brexpiprazole Rexulti Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Brigatinib Alunbrig Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Budesonide Entocort Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Budesonide Nasal Spray Rhinocort Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Budesonide Oral Inhalation Pulmicort Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Cabozantinib Cabometyx Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Cabozantinib (Thyroid Cancer) Cabometyx Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Capmatinib Tabrecta Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Clindamycin Injection ANTIROBE Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Clindamycin Topical C/T/S® Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Clindamycin Vaginal Cleocin Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Cobimetinib Cotellic Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ensitrelvir Cyclosporine Injection Atopica Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details Ensitrelvir Cyclosporine Ophthalmic Cequa Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.